Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Grégoire CourtineGrégoire Courtine was originally trained in Mathematics and Physics, but received his PhD degree in Experimental Medicine from the University of Pavia, Italy, and the INSERM Plasticity and Motricity, in France, in 2003. From 2004-2007, he held a Post-doctoral Fellow position at the Brain Research Institute, University of California at Los Angeles (UCLA) under the supervision of Dr. Reggie Edgerton, and was a research associate for the Christopher and Dana Reeve Foundation (CDRF). In 2008, he became Assistant Professor at the faculty of Medicine of the University of Zurich where he established his own research laboratory. In 2012, he was nominated Associate Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) where he holds the International paraplegic foundation (IRP) chair in spinal cord repair at the Center for Neuroprosthetics and the Brain Mind Institute. He published several articles proposing radically new approaches for restoring function after spinal cord injury, which were discussed in national and international press extensively. He received numerous honors and awards such as the 2007 UCLA Chancellors award for excellence in post-doctoral research and the 2009 Schellenberg Prize for his innovative research in spinal cord injury awarded by the International Foundation of Research in Paraplegia.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Rolf GruetterAwards:
1999 Young Investigator Award Plenary Lectureship
, International Society for Neurochemistry
2011 Fellow
, ESMRMB
2011 Teaching Award
, Section Sciences de la Vie, EPFL
Maria del Carmen Sandi PerezACADEMIC POSITION:
Professor, Director of the Laboratory of Behavioral Genetics, Brain Mind Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland.
EDUCATION:
BS MS Salamanca, Spain, 1984
PhD Cajal Institute, CSIC, and University Autonoma of Madrid, Spain, 1988
PROFESSIONAL EXPERIENCE:
Postdoc at INSERM, Bordeaux, France, and Cajal Institute Madrid, Spain, 1989-1990
Postdoc at the Open University, UK, 1991-1992, 1996
Research Associate, Cajal Institute, CSIC, Madrid, 1993-1995
Associate Professor Tenured, UNED University, Madrid, 1996-2003
Sabbatical Professor, University of Bern, Switzerland, 2002-2003
Assistant Professor Tenure-Track, EPFL, 2003-2007
Associate Professor Tenured, EPFL, 2007-2012
Full Professor, EPFL, 2012-
Director, Brain Mind Institute, EPFL, 2012-
PRINCIPAL BOARDS:
President, European Brain and Behavior Society (EBBS), 2009-2012
Editor-in-Chief Frontiers in Behavioral Neuroscience
Member of Scientific Advisory Panel, European College Neuropsychopharmacology (ECNP)
Member of the European Dana Alliance for the Brain (EDAB)
Associate Editor Frontiers in Neuroscience
Editorial Board Member Neurobiology of Learning and Memory
Editorial Board Member Journal of Psychiatry Research
Editorial Board Member Stress
Editorial Board Member Biology of Mood and Anxiety Disorders
Editorial Board Member Neuroscience and Biobehavioral Reviews
Georges WagnièresGeorges Wagnières a obtenu son diplôme (MSc) en physique à l'Université de Lausanne, Suisse, en 1986. Il a reçu son doctorat ès science (PhD) en physique (Optique Biomédicale) de l'Ecole Polytechnique Fédérale de Lausanne (EPFL) en 1992, et a effectué un travail de postdoctorat dans les "Wellman Laboratories of Photomedicine" (Harvard Medical School) situés à Boston, MA, USA, en 1993 et 1994. Il a aussi obtenu, en 2001, un "Master in management of technology" délivré par l'Ecole des Hautes Etudes Commerciales (HEC) de l'Université de Lausanne et l'EPFL. Depuis 1994, il gère un groupe de recherche de l'EPFL actif dans les domaines suivants: - Caractérisation et détection de lésions cancéreuses par spectroscopie et imagerie de fluorescence ainsi que par imagerie à fort grossissement. - Traitement du cancer ainsi que d'autres pathologies associées à des désordres immunologiques (maladie de Crohn, Colite ulcéreuse) ou vasculaires par thérapie photodynamique (PDT). - Développement préclinique et clinique de photosensibilisateurs, de marqueurs fluorescents et d'instruments optiques pour le photodiagnostic. - Traitement de diverses pathologies, y compris les maladies neuro-dégénératives (Parkinson, Alzheimer), par photobiomodulation. - Monitorage de la dose optique pour la PDT basée sur l'imagerie de fluorescence de photosensibilisateurs. - Induction de l'extravasation d'agent chimiothérapeutiques par PDT. - Mesure in vivo de la concentration d'oxygène dans des tissus biologiques par spectroscopie et imagerie optiques résolues en temps. - Monitorage d'un traitement au laser de la rétine par imagerie de reflectance. - Développement de distributeurs de lumière pour des applications biomédicales. - Dosimétrie de lumière / Radiométrie. - Spectroscopie et imagerie en optique biomédicale. Georges Wagnières est aussi co-fondateur et a présidé une société "spin-off" de l'EPFL: - Medlight SA, fondée en 1997, qui développe, produit et commercialise des distributeurs de lumière pour la thérapie photodynamique. Georges Wagnières est l'auteur et co-auteur de plus de 235 articles scientifiques dont 150 ont été publiés dans des revues internationales ayant un comité de relecture (review board). De plus, il est inventeur de 18 brevets. Finalement, il supervise ou a supervisé 12 doctorants et enseigne actuellement à l'EPFL l'optique biomédicale et la photomédecine au niveaux "master". Ces cours sont aussi donnés à l'Ecole doctorale (EDCH, EDSV) de l'EPFL. Finalement, il donne le cours intitulé "Physique Générale I" aux biologistes de première année inscrits à l'Ecole de Biologie de l'Université de Lausanne. PUBLICATIONS PRINCIPALES: SVP visiter: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ 